Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Weight Loss Methods in Metabolic Syndrome
NCT06410352Phase 4Recruiting
- Sponsor
- University Medical Center of Southern Nevada
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide and empagliflozin in metabolic syndrome, type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by University Medical Center of Southern Nevada. Primary endpoints: Reduction in body weight at 24 weeks, Fasting blood glucose at 24 weeks and 3 more. Started Mar 2024; status: recruiting.
02
Drugs
semaglutideempagliflozin
03
Conditions
metabolic syndrometype 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06410352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06410352.